In a bold move to safeguard its pioneering work, Magnus Medical has sent cease-and-desist letters to companies it believes are infringing on the intellectual property behind its breakthrough SAINT neuromodulation therapy for treatment-resistant depression. What this really means is that Magnus is drawing a line in the sand to protect the integrity of this cutting-edge treatment and ensure patients have access to the highest quality, clinically-validated care.
Guarding the SAINT Protocol
Magnus holds exclusive rights to a portfolio of U.S. patents assigned to Stanford University that cover the systems and methods behind its accelerated theta-burst stimulation (aTBS) protocol, known as SAINT. This therapy, which was the first of its kind to receive FDA clearance, utilizes neuroimaging and a proprietary algorithm to precisely target and modulate brain circuitry in a way that can rapidly alleviate symptoms of major depressive disorder.
As CNN recently reported, SAINT has demonstrated impressive results in clinical trials, with patients experiencing dramatic improvements in their depression within just five days of treatment. The company is now working to expand access to this transformative therapy, which is why it's taking a firm stance against potential infringers.
Protecting Patients and Innovation
"Protecting this IP ensures patients receive rigorously validated accelerated treatment," said Brandon Bentzley, M.D., Ph.D., co-founder and chief science officer of Magnus Medical. "Patients deserve treatments backed by the highest quality peer-reviewed science and real-world outcomes."
The bigger picture here is that Magnus is not only defending its own intellectual property, but also safeguarding the future of innovation in mental health treatment. By aggressively protecting the breakthroughs embodied in its SAINT protocol, the company is ensuring that patients have access to the most cutting-edge, evidence-based therapies available.
As the World Health Organization has emphasized, access to effective mental health care is a critical global health priority. Magnus' actions demonstrate a commitment to upholding the highest standards and delivering on that imperative.